Current Edition

MABp1

XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis

First Patient Begins Therapy with MABp1 for Treatment of Atopic Dermatitis XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its …

Continue Reading →